Definium Therapeutics (MMQ0) Stock Statistics & Valuation Metrics
Total Valuation
Definium Therapeutics has a market cap or net worth of EUR 4.36B. The enterprise value is EUR 4.16B.
- Market Cap
- EUR 4.36B
- Enterprise Value
- EUR 4.16B
Share Statistics
Definium Therapeutics has 134,366,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 134,366,940
- Owned by Insiders
- 3.25%
- Owned by Institutions
- 35.13%
Financial Efficiency
Definium Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -44.54%.
- Return on Equity (ROE)
- -0.55
- Return on Assets (ROA)
- -0.42
- Return on Invested Capital (ROIC)
- -44.54%
- Return on Capital Employed (ROCE)
- -0.45
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.73M
- Employee Count
- 106
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Definium Therapeutics is -9.32. Definium Therapeutics’s PEG ratio is 0.13.
- PE Ratio
- -9.32
- PS Ratio
- 0.00
- PB Ratio
- 3.86
- Price to FCF
- -25.82
- Price to Operating Cash Flow
- -21.27
- PEG Ratio
- 0.13
Income Statement
In the last 12 months, Definium Therapeutics had revenue of 0 and earned -183.79M in profits. Earnings per share was -2.06.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -166.31M
- Pretax Income
- -183.79M
- Net Income
- -183.79M
- EBITDA
- -178.31M
- Earnings Per Share (EPS)
- -2.06
Cash Flow
In the last 12 months, operating cash flow was -166.87M and capital expenditures 0, giving a free cash flow of -166.87M billion.
- Operating Cash Flow
- -166.87M
- Free Cash Flow
- -166.87M
- Free Cash Flow per Share
- -1.51
Dividends & Yields
Definium Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.83%
- Earnings Yield
- -9.86%
Stock Price Statistics
- Beta
- 0.89
- 52-Week Price Change
- 185.84%
- 50-Day Moving Average
- 32.72
- 200-Day Moving Average
- 25.72
- Relative Strength Index (RSI)
- 51.33
- Average Volume (3m)
- 144
Important Dates
Definium Therapeutics upcoming earnings date is Nov 09, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 09, 2026
- Ex-Dividend Date
- ―
Financial Position
Definium Therapeutics as a current ratio of 6.29, with Debt / Equity ratio of 0.00%
- Current Ratio
- 6.29
- Quick Ratio
- 6.29
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.45
- Interest Coverage Ratio
- -30.34
Taxes
In the past 12 months, Definium Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Definium Therapeutics EV to EBITDA ratio is -11.00, with an EV/FCF ratio of -22.39.
- EV to Sales
- 0.00
- EV to EBITDA
- -11.00
- EV to Free Cash Flow
- -22.39
- EV to Operating Cash Flow
- -22.39
Balance Sheet
Definium Therapeutics has EUR 1.08B in cash and marketable securities with EUR 36.47M in debt, giving a net cash position of EUR 1.05B billion.
- Cash & Marketable Securities
- EUR 1.08B
- Total Debt
- EUR 36.47M
- Net Cash
- EUR 1.05B
- Net Cash Per Share
- EUR 7.80
- Tangible Book Value Per Share
- EUR 8.12
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Definium Therapeutics is EUR 65.12, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 65.12
- Price Target Upside
- 100.38% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 16
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -135.89%
Scores
- Smart Score
- 9
- AI Score
- ―
